Welcome to Plenary Session.

I'm your host, Dr. Vinay Prasad.

I'm a practicing hematologist, oncologist, and I'm associate professor of medicine.

I'm interested in issues at the intersection of medicine, oncology, and health policy, and that's what you're going to get on this podcast.

Welcome to Season 2.

Well, I'm back. I'm back here in the studio at Plenary Session. I'm back in the new HQ.

We've moved from the old office where there was a speaker in the ceiling that was playing a noise-canceling sound that caused some static disruption

to a new office, one floor down, where it is, I hope, very quiet.

So we're able to record in peace here in the new plenary session, HQ.

And we're going to have some very interesting things for you in the new year.

On this week's episode, we're going to have a discussion of the use of

tristhusimab in latter lines of therapy for Herodoo Positive Medesthetic Breast Cancer.

We're going to take a listener question on the Kaplan Meyer curve, and we're going to talk

a little bit about Patreon, so stay tuned.

But first, a thanks.

I want to thank those of you who've gone online and support this podcast on patreon.com.

Patreon subscribers get access to the slides from lectures I give on plenary session.

I also want to thank the hundreds of you who've gone to the iTunes store and reviewed

this podcast.

We appreciate that feedback.

I also want to thank the dozens of you who've written reviews. A written review goes a long way. What can Plenary Session do for you?

Email us your questions at Plenary Session podcast at gmail.com. Tweet to us at Plenary underscore

...